spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BBI Solutions adds more antibodies to product range

BBI Solutions

BBI Solutions has continued to invest in its portfolio of antibodies and today announced the launch of 10 infectious disease markers, 3 inflammatory markers, 2 fertility markers and an additional cardiac marker.

BBI Solutions (BBI) is in a rapid period of expansion and growth with recent announcements of a £14m investment into a global headquarters for the BBI Group and a recent acquisition of Maine Biotechnology Services. This further investment in to the expansion of BBI’s antibodies portfolio forms another part of the company’s growth plans as they continually aim to meet the growing demands of their customers.

BBI’s new infectious disease markers include H. pylori, Influenza A and B, E. coli O157, Campylobacter and Legionella pneumophila. BBI have also released antibodies for three inflammatory markers; Calprotectin, CRP and IL-6, two fertility markers; AMH and Estriol and Myoglobin antibodies as a cardiac marker.

James Steggles, BBI’s Antibodies Commercial Manager explained “we are pleased to be able to offer this range of high quality antibodies that test developers can use with confidence as part of their research and development assay programs. As they aim to improve diagnosis of key diseases and conditions.”

BBI’s mission is to deliver exceptional products and technologies that people rely on to enjoy a better quality of life. “We have selected these antibodies following requests from our customers. They also work towards achieving our mission and our growth plans”, continued James.

All of BBI’s new antibodies have either been tested in lateral flow or ELISA assays, many are already being used in commercial assays and there are a number of recommended matched pairs, which will save time and money in customer’s screening processes. To discover more about these antibodies and their matched pairs or to order a sample visit our website or call today www.bbisolutions.com +44 (0) 2920 747 232.

About
BBI Solutions is a leading manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market. BBI has grown from a small specialist company to a global business with manufacturing sites spanning three countries.

Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.

BBI Solutions offer contract development and manufacturing services with a core focus on gold conjugation and lateral flow test manufacture.

BBI Solutions is part of the BBI Group.

www.bbisolutions.com

Media Contact
Laura Baker
T: 02920 747232
E: LauraBaker@bbisolutions.com
phone 08444 176393
email LauraBaker@bbisolutions.com
web www.bbisolutions.com
email 73 Ty Glas Avenue, Cardiff, CF14 5DX-
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Media Advisory AD Communications appointed PR Agency for PPMA

Please be advised that the PPMA Group of Associations has appointed AD Communications as PR agency with responsibility for its corporate and PPMA Show accounts.
More info >>


White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement